Analyzing TransEnterix (OTCMKTS:TRXDW) and Biosig Technologies (NASDAQ:STEX)

Biosig Technologies (NASDAQ:STEX) and TransEnterix (OTCMKTS:TRXDW) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Volatility and Risk

Biosig Technologies has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, TransEnterix has a beta of 2.56, suggesting that its share price is 156% more volatile than the S&P 500.

Profitability

This table compares Biosig Technologies and TransEnterix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	N/A	-64.96%
TransEnterix	-2,149.15%	-83.74%	-64.94%

Valuation & Earnings

This table compares Biosig Technologies and TransEnterix”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40,000.00	13,087.20	-$10.33 million	($1.35)	-2.43
TransEnterix	$8.53 million	2.51	-$154.20 million	($4.22)	-0.04

Biosig Technologies has higher earnings, but lower revenue than TransEnterix. Biosig Technologies is trading at a lower price-to-earnings ratio than TransEnterix, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Biosig Technologies and TransEnterix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1	0	0	0	1.00
TransEnterix	0	0	0	0	0.00

Insider & Institutional Ownership

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 8.2% of TransEnterix shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 3.1% of TransEnterix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Biosig Technologies beats TransEnterix on 7 of the 12 factors compared between the two stocks.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

About TransEnterix

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.